Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or -ultralow breast cancer.
Scientists have developed new light-sensitive chemicals that can radically improve the treatment of aggressive cancers with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback